Literature DB >> 28463161

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Ethan Basch1, Stephanie L Pugh2, Amylou C Dueck3, Sandra A Mitchell4, Lawrence Berk5, Shannon Fogh6, Lauren J Rogak7, Marcha Gatewood8, Bryce B Reeve9, Tito R Mendoza10, Ann M O'Mara4, Andrea M Denicoff4, Lori M Minasian4, Antonia V Bennett9, Ann Setser11, Deborah Schrag12, Kevin Roof13, Joan K Moore14, Thomas Gergel15, Kevin Stephans16, Andreas Rimner17, Albert DeNittis18, Deborah Watkins Bruner8.   

Abstract

PURPOSE: To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter clinical trial using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). METHODS AND MATERIALS: Patients enrolled in NRG Oncology's RTOG 1012 (Prophylactic Manuka Honey for Reduction of Chemoradiation Induced Esophagitis-Related Pain during Treatment of Lung Cancer) were asked to self-report 53 PRO-CTCAE items representing 30 symptomatic AEs at 6 time points (baseline; weekly ×4 during treatment; 12 weeks after treatment). Reporting was conducted via wireless tablet computers in clinic waiting areas. Compliance was defined as the proportion of visits when an expected PRO-CTCAE assessment was completed.
RESULTS: Among 226 study sites participating in RTOG 1012, 100% completed 35-minute PRO-CTCAE training for clinical research associates (CRAs); 80 sites enrolled patients, of which 34 (43%) required tablet computers to be provided. All 152 patients in RTOG 1012 agreed to self-report using the PRO-CTCAE (median age 66 years; 47% female; 84% white). Median time for CRAs to learn the system was 60 minutes (range, 30-240 minutes), and median time for CRAs to teach a patient to self-report was 10 minutes (range, 2-60 minutes). Compliance was high, particularly during active treatment, when patients self-reported at 86% of expected time points, although compliance was lower after treatment (72%). Common reasons for noncompliance were institutional errors, such as forgetting to provide computers to participants; patients missing clinic visits; Internet connectivity; and patients feeling "too sick."
CONCLUSIONS: Most patients enrolled in a multicenter chemoradiotherapy trial were willing and able to self-report symptomatic AEs at visits using tablet computers. Minimal effort was required by local site staff to support this system. The observed causes of missing data may be obviated by allowing patients to self-report electronically between visits, and by using central compliance monitoring. These approaches are being incorporated into ongoing studies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28463161      PMCID: PMC5557037          DOI: 10.1016/j.ijrobp.2017.02.002

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Comparative reliability and validity of chronic pain intensity measures.

Authors:  M P Jensen; J A Turner; J M Romano; L D Fisher
Journal:  Pain       Date:  1999-11       Impact factor: 6.961

2.  Chemotherapy and quality of life in NSCLC PS 2 patients.

Authors:  Nina Helbekkmo; Hans H Strøm; Stein H Sundstrøm; Ulf Aasebø; Christian Von Plessen; Roy M Bremnes
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

3.  Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.

Authors:  Chandra P Belani; Jose R Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin V Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panos Fidias; Michael Millward; Frank Fossella
Journal:  Lung Cancer       Date:  2006-06-19       Impact factor: 5.705

4.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

Authors:  Erik K Fromme; Kristine M Eilers; Motomi Mori; Yi-Ching Hsieh; Tomasz M Beer
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

5.  Agreement between patient-reported symptoms and their documentation in the medical record.

Authors:  Serguei V Pakhomov; Steven J Jacobsen; Christopher G Chute; Veronique L Roger
Journal:  Am J Manag Care       Date:  2008-08       Impact factor: 2.229

Review 6.  A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer.

Authors:  Tawee Tanvetyanon; Heloisa P Soares; Benjamin Djulbegovic; Paul B Jacobsen; Gerold Bepler
Journal:  J Thorac Oncol       Date:  2007-12       Impact factor: 15.609

  6 in total
  36 in total

Review 1.  Revisiting the dose constraints for head and neck OARs in the current era of IMRT.

Authors:  N Patrik Brodin; Wolfgang A Tomé
Journal:  Oral Oncol       Date:  2018-09-08       Impact factor: 5.337

2.  Nurse-Delivered Symptom Assessment for Individuals With Advanced Lung Cancer.

Authors:  Marie Flannery; Karen F Stein; David W Dougherty; Supriya Mohile; Joseph Guido; Nancy Wells
Journal:  Oncol Nurs Forum       Date:  2018-09-01       Impact factor: 2.172

3.  Patient-Reported Outcomes in Surgical Oncology: An Overview of Instruments and Scores.

Authors:  Joseph D Phillips; Sandra L Wong
Journal:  Ann Surg Oncol       Date:  2019-08-28       Impact factor: 5.344

4.  Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Arlene E Chung; Kimberly Shoenbill; Sandra A Mitchell; Amylou C Dueck; Deborah Schrag; Deborah W Bruner; Lori M Minasian; Diane St Germain; Ann M O'Mara; Paul Baumgartner; Lauren J Rogak; Amy P Abernethy; Ashley C Griffin; Ethan M Basch
Journal:  J Am Med Inform Assoc       Date:  2019-04-01       Impact factor: 4.497

5.  Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Authors:  Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss
Journal:  Oncologist       Date:  2018-12-14

6.  Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.

Authors:  Kirsten A Nyrop; Allison M Deal; Bryce B Reeve; Ethan Basch; Yi Tang Chen; Ji Hye Park; Shlomit S Shachar; Lisa A Carey; Katherine E Reeder-Hayes; Elizabeth C Dees; Trevor A Jolly; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Jordan T Lee; William A Wood; Hyman B Muss
Journal:  Cancer       Date:  2020-04-21       Impact factor: 6.860

7.  Incorporating Multiple Perspectives Into the Development of an Electronic Survivorship Platform for Head and Neck Cancer.

Authors:  Talya Salz; Rebecca B Schnall; Mary S McCabe; Kevin C Oeffinger; Stacie Corcoran; Andrew J Vickers; Andrew L Salner; Ellen Dornelas; Nirupa J Raghunathan; Elizabeth Fortier; Janet McKiernan; David J Finitsis; Susan Chimonas; Shrujal Baxi
Journal:  JCO Clin Cancer Inform       Date:  2018-12

8.  Feasibility of Wearable Physical Activity Monitors in Patients With Cancer.

Authors:  Arjun Gupta; Tyler Stewart; Nizar Bhulani; Ying Dong; Zain Rahimi; Kimberli Crane; Chad Rethorst; Muhammad S Beg
Journal:  JCO Clin Cancer Inform       Date:  2018-12

9.  Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.

Authors:  Shota Tanaka; Iori Sato; Masamichi Takahashi; Terri S Armstrong; Charles S Cleeland; Tito R Mendoza; Akitake Mukasa; Shunsaku Takayanagi; Yoshitaka Narita; Kiyoko Kamibeppu; Nobuhito Saito
Journal:  Jpn J Clin Oncol       Date:  2020-07-09       Impact factor: 3.019

10.  Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

Authors:  Ethan Basch; Amylou C Dueck; Lauren J Rogak; Sandra A Mitchell; Lori M Minasian; Andrea M Denicoff; Jennifer K Wind; Mary C Shaw; Narre Heon; Qian Shi; Brenda Ginos; Garth D Nelson; Jeffrey P Meyers; George J Chang; Harvey J Mamon; Martin R Weiser; Tatjana Kolevska; Bryce B Reeve; Deborah Watkins Bruner; Deborah Schrag
Journal:  J Clin Oncol       Date:  2018-09-11       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.